Survival rates for idiopathic pulmonary fibrosis are worse than all solid cancers except for lung and pancreatic cancer. | ...

The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis (PF) research, education and advocacy ...

Waltham, Massachusetts Friday, November 15, 2024, 15:00 Hrs [IST] ...

Cereno Scientific has secured loan financing to continue developing CS1, its lead therapeutic candidate for pulmonary ...

Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...

As physicians we take an oath to do no harm, yet are trapped providing care in a system that leaves patients confined and at ...

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company ...